News and Trends 16 Jul 2018 CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage Researchers at the Wellcome Trust Sanger Institute in the UK have found that gene editing with CRISPR-Cas9 can cause significantly more off-target damage to the DNA than previously thought. … July 16, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Maxion Therapeutics raises $16M to target GPCRs Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors… February 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most… September 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Genetically Engineered Mosquitoes will arrive in India to fight Dengue Oxitec is preparing to start trials testing its solution to reduce the population of disease-transmitting insects in India with its own genetically modified mosquitoes. Oxitec, a spin-out from Oxford University,… January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 New British Biotech-Academia Alliance takes on Cardiovascular Disease Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors… January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the… November 4, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of… June 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2017 Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will… July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2018 Gene Therapy Could Prevent Deadly Brain Disease An international research team used gene therapy to prevent Gaucher disease, a potentially deadly neurodegenerative condition, in mice. The approach could eventually be used to treat human diseases in the… July 17, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 16 Aug 2019 This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells It’s time to go to London, UK, this week. The UK biotech AstronauTx is developing drugs that could slow the progress of Alzheimer’s disease by aiming at star-shaped cells in… August 16, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Research discovery may help diagnose and treat cancer and brain disorders Researchers at Queen’s University Belfast in Northern Ireland have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain… August 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 New Replay HSV gene therapy company Telaria to focus on skin diseases Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its… November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email